Advances in clinical research on transarterial chemoembolization combining with systemic durgs in hepatocellular carcinoma

VernacularTitle:经导管肝动脉栓塞化疗联合系统性药物治疗肝细胞癌的研究进展
Author: Weiran DU ¹ ; Chengxiang GUO ; Xueli BAI ; Tingbo LIANG
Author Information

1. 浙江大学医学院附属第一医院肝胆胰外科　浙江省胰腺病研究重点实验室，杭州　310003
Keywords: Carcinoma, hepatocellular; Transarterial chemoembolization; Targeted therapy; Immunotherapy
From: Chinese Journal of Hepatobiliary Surgery 2023;29(12):949-955
CountryChina
Language:Chinese
Abstract: Hepatocellular carcinoma (HCC) is one of the malignant tumors of the digestive system with the highest morbidity and mortality. The vast majority of patients with intermdiate and advanced HCC have low response rates and poor long-term survival to a series of treatments mainly based on transcatheter arterial chemoembolization (TACE). In recent years, molecular targeted therapy, immunotherapy and their combination with TACE have developed rapidly. This article reviews the research progress of TACE combined with systemic drug therapy in HCC and looks forward to the future direction of precise treatment of HCC.